Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (874)	12/21/1998 8:31:00 PM
From: David S.	Respond to of 965

To: Henry Niman who wrote (874)	12/21/1998 9:30:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 965

Thanks, Henry. Might explain today's move, although that ReoPro works well at six months is not exactly new news: biz.yahoo.com Should help CORR as well. Note the comment in the Bloomberg story: Researchers now are studying the drugs in combination with other medications, such as Genentech Inc.'s Activase and Centocor Inc.'s Retavase, that dissolve existing clots. I have always maintained this is the key to CNTO - if they can convincingly demonstrate the efficacy and safety of ReoPro and Retavase used together they will have a winner. The fact that Activase might work just as well in combination with ReoPro (as indicated by preliminary studies)is beside the point - there are going to be lots of ReoPro/Retavase studies and many fewer ReoPro/Activase or (Integrilin/Aggrastat)/(Activase/Retavase) studies. Peter